ReviewThe Lancet. Infectious diseases2021
Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology.
Review in The Lancet. Infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 272 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
272 citing papers in PubMed, 411 citations in OpenAlex.
- Evaluation of the cytochrome P450-mediated drug interaction profile of olorofim.Antimicrobial agents and chemotherapy · 2026Trial
- Fosmanogepix for the Treatment of Invasive Mold Diseases Caused by Aspergillus Species and Rare Molds: A Phase 2, Open-Label Study (AEGIS).Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Trial
- Novel model to predict risk of invasive fungal infection and fungal prophylaxis timing.Microbiology spectrum · 2025Trial
- From misdiagnosis to precision management: Thoracic vertebral infection caused byMedical mycology case reports · 2026Article
- First report of proven Fusarium brachygibbosum sinusitis in a paediatric patient with acute myeloblastic leukaemia.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Phaeohyphomycosis in a Solid Organ Transplant Recipient: Case Report of a New Pathogenic Species of Kirschsteiniothelia.Mycopathologia · 2026Article
- Performance of the Sensititre YeastOne assay compared with EUCAST E.Def 9.4 againstJAC-antimicrobial resistance · 2026Article
- The Brief Case: Recalcitrant cutaneous and subcutaneous knee infection caused byJournal of clinical microbiology · 2026Review
- Establishment of epidemiological cutoff values againstJournal of clinical microbiology · 2026Article
- Migratory Pulmonary Infiltrates Mimicking Malignancy, Tuberculosis, and Sarcoidosis in an Apparently Immunocompetent Adult: A Case of Tissue-Proven Invasive Fungal Disease Due to a Non-Journal of fungi (Basel, Switzerland) · 2026Article
- Article
- Review
- Non-Candida fungal cholecystitis - an uncommon occurrence even in the right host.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- Therapeutic Failure in Invasive Fungal Infections: Beyond Antifungal Resistance-A Narrative Review.Journal of fungi (Basel, Switzerland) · 2026Review
- 30 years in service, 1996-2026: Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).Annals of hematology · 2026Review
- Asian consensus on diagnostic algorithm for invasive pulmonary fungal diseases in high-burden settings.Journal of translational internal medicine · 2026Article
- Molecular Mechanisms, Diagnosis, and Therapeutic Strategies of Antifungal Resistance in Filamentous Fungi.Journal of fungi (Basel, Switzerland) · 2026Review
- MYcology Stewardship Tool (MyST): a retrospective, descriptive multidisciplinary team review of antifungal prescribing practice in a UK tertiary centre.JAC-antimicrobial resistance · 2026Article
- Fungal diagnostics and antifungal drug access in Latin America and the Caribbean: an ESCMID EFISG multinational survey.Nature communications · 2026Article
- Diagnostic Failure in Invasive Fungal Infections: Causes, Clinical Consequences, and Mitigation Strategies.Journal of fungi (Basel, Switzerland) · 2026Review
212 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
45 authors at 20 institutions in 24 countries.
Funding
Abstract
With increasing numbers of patients needing intensive care or who are immunosuppressed, infections caused by moulds other than Aspergillus spp or Mucorales are increasing. Although antifungal prophylaxis has shown effectiveness in preventing many invasive fungal infections, selective pressure has caused an increase of breakthrough infections caused by Fusarium, Lomentospora, and Scedosporium species, as well as by dematiaceous moulds, Rasamsonia, Schizophyllum, Scopulariopsis, Paecilomyces, Penicillium, Talaromyces and Purpureocillium species. Guidance on the complex multidisciplinary management of infections caused by these pathogens has the potential to improve prognosis. Management routes depend on the availability of diagnostic and therapeutic options. The present recommendations are part of the One World-One Guideline initiative to incorporate regional differences in the epidemiology and management of rare mould infections. Experts from 24 countries contributed their knowledge and analysed published evidence on the diagnosis and treatment of rare mould infections. This consensus document intends to provide practical guidance in clinical decision making by engaging physicians and scientists involved in various aspects of clinical management. Moreover, we identify areas of uncertainty and constraints in optimising this management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.